Deuterium MR spectroscopy: potential applications in oncology research.

Autor:	Bitencourt AGV; Imaging Department, A. C. Camargo Cancer Center, São Paulo, 01525-001, Brazil.; Diagnósticos da América S.A., São Paulo, 04321-120, Brazil., Bhowmik A; Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, United States., Marcal Filho EFL; Imaging Department, A. C. Camargo Cancer Center, São Paulo, 01525-001, Brazil.; Diagnósticos da América S.A., São Paulo, 04321-120, Brazil., Lo Gullo R; Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, United States., Mazaheri Y; Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, United States.; Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, United States., Kapetas P; Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, United States.; Department of Biomedical Imaging and Image-Guided Therapy, Medical University of Vienna, 1090 Vienna, Austria., Eskreis-Winkler S; Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, United States., Young R; Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, United States., Pinker K; Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, United States., Thakur SB; Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, United States.; Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, United States.
Jazyk:	angličtina
Zdroj:	BJR open [BJR Open] 2024 Aug 05; Vol. 6 (1), pp. tzae019. Date of Electronic Publication: 2024 Aug 05 (Print Publication: 2024).
DOI:	10.1093/bjro/tzae019
Abstrakt:	Metabolic imaging in clinical practice has long relied on PET with fluorodeoxyglucose (FDG), a radioactive tracer. However, this conventional method presents inherent limitations such as exposure to ionizing radiation and potential diagnostic uncertainties, particularly in organs with heightened glucose uptake like the brain. This review underscores the transformative potential of traditional deuterium MR spectroscopy (MRS) when integrated with gradient techniques, culminating in an advanced metabolic imaging modality known as deuterium MRI (DMRI). While recent advancements in hyperpolarized MRS hold promise for metabolic analysis, their widespread clinical usage is hindered by cost constraints and the availability of hyperpolarizer devices or facilities. DMRI, also denoted as deuterium metabolic imaging (DMI), represents a pioneering, single-shot, and noninvasive paradigm that fuses conventional MRS with nonradioactive deuterium-labelled substrates. Extensively tested in animal models and patient cohorts, particularly in cases of brain tumours, DMI's standout feature lies in its seamless integration into standard clinical MRI scanners, necessitating only minor adjustments such as radiofrequency coil tuning to the deuterium frequency. DMRI emerges as a versatile tool for quantifying crucial metabolites in clinical oncology, including glucose, lactate, glutamate, glutamine, and characterizing IDH mutations. Its potential applications in this domain are broad, spanning diagnostic profiling, treatment response monitoring, and the identification of novel therapeutic targets across diverse cancer subtypes. Competing Interests: K.P. reports a relationship with the European Society of Breast Imaging, Bayer, Siemens Healthineers, Olea Medical, and Roche entailing speaking and lecture fees, as well as a relationship with Genentech, Merantix Healthcare, AURA Health Technologies, and Guerbet entailing a consulting or advisory role. The remaining authors report no conflict of interest. (© The Author(s) 2024. Published by Oxford University Press on behalf of the British Institute of Radiology.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu